Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 3Neuroblastoma 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 25Cisplatin 24Carboplatin 19Paclitaxel 16Magnetic Resonance Spectroscopy 16Specimen Handling 14Pemetrexed 12durvalumab 10Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Gemcitabine 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × lorlatinib × 1 year × Clear all
NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Pfizer

Phase 4 Completed
71 enrolled 26 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡